JAK inhibitors plus standard of care vs placebo or usual care
All‐cause mortality (up to day 60) · hospitalised people with confirmed SARS‐CoV‐2 infection
1 finding from 1 review
- no estimate extracted2 studies · 1626 participantsHigh
Findings
What do systematic reviews say?
959 questions · 987 findings · 78 reviews · Haematology
No studies found 256 · 25.9%GRADE not reported 64 · 6.5%Very low 207 · 21%Low 247 · 25%Moderate 163 · 16.5%High 50 · 5.1%
JAK inhibitors plus standard of care vs placebo or usual care
Improvement in clinical status: discharged alive or hospitalised, but no longer requiring ongoing medical care (up to day 28) · hospitalised people with confirmed SARS‐CoV‐2 infection
1 finding from 1 review
- no estimate extracted4 studies · 10802 participantsModerate
JAK inhibitors plus standard of care vs placebo or usual care
Clinical worsening: new need for invasive mechanical ventilation or death · hospitalised people with confirmed SARS‐CoV‐2 infection
1 finding from 1 review
- no estimate extracted2 studies · 9417 participantsModerate
JAK inhibitors plus standard of care vs placebo or usual care
Adverse events: all grades · hospitalised people with confirmed SARS‐CoV‐2 infection
1 finding from 1 review
- no estimate extracted3 studies · 1885 participantsModerate
JAK inhibitors plus standard of care vs placebo or usual care
Serious adverse events · hospitalised people with confirmed SARS‐CoV‐2 infection
1 finding from 1 review
- no estimate extracted4 studies · 2901 participantsModerate
JAK inhibitors plus standard of care vs placebo or usual care
Secondary infection · hospitalised people with confirmed SARS‐CoV‐2 infection
1 finding from 1 review
- no estimate extracted4 studies · 10041 participantsLow
Fluvoxamine plus standard care vs placebo + standard care
All‐cause mortality (at day 28) · symptomatic people with COVID‐19
Fluvoxamine plus standard care showed no clear difference in all‐cause mortality (at day 28) compared with placebo plus standard care (low certainty).
1 finding from 1 review
- RR 0.69 [0.38, 1.27]2 studies · 1649 participantsLow
Fluvoxamine plus standard care vs placebo + standard care
All‐cause admission to hospital or death (before hospital admission) · symptomatic people with COVID‐19
Fluvoxamine plus standard care showed no clear difference in all‐cause admission to hospital or death (before hospital admission) compared with placebo plus standard care (low certainty).
1 finding from 1 review
- RR 0.55 [0.16, 1.89]2 studies · 1649 participantsLow
Fluvoxamine plus standard care vs placebo + standard care
Resolution of symptoms · symptomatic people with COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Fluvoxamine plus standard care vs placebo + standard care
Quality of life at longest · symptomatic people with COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Fluvoxamine plus standard care vs placebo + standard care
Serious adverse events during the study period · symptomatic people with COVID‐19
It is very uncertain whether fluvoxamine plus standard care changes serious adverse events (during study period) compared with placebo plus standard care (very low certainty).
1 finding from 1 review
- RR 0.56 [0.15, 2.03]2 studies · 1649 participantsVery low
Fluvoxamine plus standard care vs placebo + standard care
Adverse events during treatment period · symptomatic people with COVID‐19
It is very uncertain whether fluvoxamine plus standard care changes any adverse events (during study period) compared with placebo plus standard care (very low certainty).
1 finding from 1 review
- RR 1.06 [0.82, 1.37]2 studies · 1649 participantsVery low
Fluvoxamine plus standard care vs placebo + standard care
Suicide or suicide attempt (at longest · symptomatic people with COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Intervention not reported
Complete haematological response at 12 months · adults with newly diagnosed warm AIHA
The intervention may leads to higher complete haematological response at 12 months (low certainty).
1 finding from 1 review
- Disease‐modifying treatments for primary autoimmune haemolytic anaemia 2021 · Cochrane Headline outcomes onlyRR 2.13 [1.34, 3.4]2 studies · 96 participantsLow
Intervention not reported
Frequency of adverse events at two, six and 12 months · adults with newly diagnosed warm AIHA
The review found no eligible studies for this question.
1 finding from 1 review
- Disease‐modifying treatments for primary autoimmune haemolytic anaemia 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Intervention not reported
Partial haematological response at 12 months · adults with newly diagnosed warm AIHA
It is very uncertain whether the intervention changes partial haematological response at 12 months (very low certainty).
1 finding from 1 review
- Disease‐modifying treatments for primary autoimmune haemolytic anaemia 2021 · Cochrane Headline outcomes onlyRR 3 [0.13, 68.57]1 study · 32 participantsVery low
Intervention not reported
Overall survival at six and 12 months · adults with newly diagnosed warm AIHA
The review found no eligible studies for this question.
1 finding from 1 review
- Disease‐modifying treatments for primary autoimmune haemolytic anaemia 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Intervention not reported
Relapse‐free survival at six and 12 months · adults with newly diagnosed warm AIHA
The review found no eligible studies for this question.
1 finding from 1 review
- Disease‐modifying treatments for primary autoimmune haemolytic anaemia 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Intervention not reported
RBC transfusion requirement after treatment at 12 months · adults with newly diagnosed warm AIHA
It is very uncertain whether the intervention changes RBC transfusion requirement after treatment at 12 months (very low certainty).
1 finding from 1 review
- Disease‐modifying treatments for primary autoimmune haemolytic anaemia 2021 · Cochrane Headline outcomes onlyRR 0.8 [0.26, 2.45]1 study · 32 participantsVery low
Intervention not reported
QOL as measured by validated instruments at 12 months · adults with newly diagnosed warm AIHA
The review found no eligible studies for this question.
1 finding from 1 review
- Disease‐modifying treatments for primary autoimmune haemolytic anaemia 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found